Depomed (DEPO) Tops Q2 EPS by 3c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Depomed Announces Second-Quarter 2018 Financial Results
August 8, 2018 7:30 AM EDT-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise --
-- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --
-- Announces Agreement with PDL BioPharma to Monetize Royalty Stream; Company Received $20 Million in Cash --
-- Announces Planned Change in Company Name from Depomed to Assertio Therapeutics;Remains On-Track to Transition to New Corporate Headquarters in Lake Forest, Illinois --
LAKE FOREST, Ill., Aug. 08,... More
